top of page

Caribou Biosciences, Inc. (CRBU) 


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ: CRBU). Investors who purchased Caribou securities are encouraged to obtain additional information and assist the investigation.


The investigation concerns whether Caribou violated federal securities laws.


On or around July 26, 2021, Caribou conducted its initial public offering (“IPO”), selling 19 million shares of stock priced at $16.00 per share.  Then, on December 12, 2022, Caribou issued a press release “report[ing] new 12-month clinical data from cohort 1 in the ongoing ANTLER Phase 1 trial, which show long-term durability following a single infusion of CB-010 at the initial dose level 1 (40x106 CAR-T cells).”  Among other results, Caribou reported that “3 of 6 patients maintained a durable CR [complete response] at 6 months” and “2 of 6 patients maintain a long-term CR at the 12 month scan and remain on the trial”.  On this news, Caribou’s stock price fell $0.81 per share, or 9.03%, to close at $8.16 per share on December 12, 2022.


If you are aware of any facts relating to this investigation or purchased Caribou shares, and believe the proposed buyout is too low, you can assist this investigation. You can also contact Peretz Bronstein or law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 


Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.  The firm has recovered hundreds of millions of dollars for investors nationwide.  Attorney advertising. Prior results do not guarantee similar outcomes.

bottom of page